Dr. Tagliaferri is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
135 Tarry Road
San Anselmo, CA 94960Phone+1 415-480-9100
Education & Training
Alameda Health System-Highland HospitalInternship, Internal Medicine, 2002 - 2003
University of California San Francisco School of MedicineClass of 2002
Certifications & Licensure
CA State Medical License 1997 - 2026
PA State Medical License 1995 - 1996
Clinical Trials
- VG101 Phase I/II to Treat Vulvar and Vaginal Atrophy in Post-Menopausal Women Start of enrollment: 2012 Jun 01
- A Study of MF101 in Postmenopausal Women Start of enrollment: 2011 Oct 01
- A Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer Start of enrollment: 2012 Jan 01
Publications & Presentations
PubMed
- 46 citationsBempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma.Adi Diab, Scott S. Tykodi, Gregory A. Daniels, Michele Maio, Brendan D. Curti
Journal of Clinical Oncology. 2021-07-13 - 12 citationsPhase I study protocol: NKTR-255 as monotherapy or combined with daratumumab or rituximab in hematologic malignancies.Nina Shah, Miguel-Angel Perales, Cameron J. Turtle, Mitchell S. Cairo, Andrew J. Cowan
Future Oncology. 2021-06-22 - 75 citationsEngineering IL-2 to Give New Life to T Cell ImmunotherapyWillem W. Overwijk, Mary Tagliaferri, Jonathan Zalevsky
Annual Review of Medicine. 2021-01-27
Press Mentions
Nektar and Collaborators Present Late-Breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual MeetingNovember 7th, 2024- Nektar Announces Publication in Blood of Phase 1 Data for Novel IL-15 Agonist NKTR-255 in Combination with Autologous CD19-22 CAR-T Cell Therapy in Patients with B-cell Acute Lymphoblastic LeukemiaOctober 17th, 2024
- Luba Greenwood Takes the Helm at Kojin Therapeutics, Steering an All-Female C-suite; Alexion R&D Chief Packs up for Change of Scenery at VC FirmOctober 15th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
